Anne Louise Tescher
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Anne Louise Tescher has a total of 2 co-authors. Here are the top co-authors by number of shared publications:
- Benjamin J. Dixon
University of Melbourne, Victoria, Australia; Department of ENT, Head and Neck Surgery, St Vincent's Hospital, Melbourne, Australia
1 shared publication Elizabeth Rose
Univ Melbourne, Royal Victorian Eye & Ear Hosp, Dept Otolaryngol, East Melbourne, Australia
1 shared publication
Latest Publications
- Open Access
- 1 September 2024
- Published by AME Publishing Company in Australian Journal of Otolaryngology
- Vol. 7, 36
Single application of clotrimazole cream in the management of fungal otitis externa
Background: Fungal otitis externa (FOE) is a common infection of the external ear canal. FOE is often associated with tympanic membrane perforation (TMP). This may be pre-existing or caused by the infection. The potential risk of ototoxicity from topical medication provides an additional treatment challenge for these patients. In this audit, a comparison is made of outcomes for patients with FOE managed with three different treatments. We compare two topical treatments licensed for use in Australia: flumetasone pivalate/clioquinol ear drops and triamcinolone acetonide/neomycin sulphate/gramicidin/nystatin ointment, with the off-label use of clotrimazole 1% cream. This is to determine if clotrimazole (the only treatment of the three without risk of ototoxicity) is as efficacious as the current licensed treatments. Methods: A review of patients diagnosed with FOE from a single Victorian specialist Ear, Nose and Throat (ENT) hospital Emergency Department (ED) was undertaken. Data from a 6-month period (March 2021–September 2021) were collected. Any patient who had presented to the ED, was subsequently confirmed on microscopy results to have FOE, and was reviewed 2 weeks post-treatment in ENT clinic was included. Successful treatment was defined as no further treatment requirement at the 2-week review. Results: Fifty-eight patients met the inclusion criteria. Ten of 16 patients (63%) were successfully treated with flumetasone pivalate/clioquinol eardrops. Twenty of 30 patients (67%) were successfully treated with triamcinolone acetonide/neomycin sulphate/gramicidin/nystatin ointment. Seven of 12 patients (58%) were successfully treated with clotrimazole 1% cream. There was no statistically significant difference between successful treatment rates between the topical treatments (Chi-square: 0.27, P=0.87). Conclusions: Clotrimazole appears to be as efficacious in the management of FOE as other topical antifungal agents. Although used off-label, it is not associated with ototoxicity. It should be considered an appropriate first-line treatment for patients with FOE, especially in the setting of TMP.
- 1 September 2024
- Published by AME Publishing Company in Australian Journal of Otolaryngology
- Vol. 7, 36
Open AccessSingle application of clotrimazole cream in the management of fungal otitis externa
Background: Fungal otitis externa (FOE) is a common infection of the external ear canal. FOE is often associated with tympanic membrane perforation (TMP). This may be pre-existing or caused by the infection. The potential risk of ototoxicity from topical medication provides an additional treatment challenge for these patients. In this audit, a comparison is made of outcomes for patients with FOE managed with three different treatments. We compare two topical treatments licensed for use in Australia: flumetasone pivalate/clioquinol ear drops and triamcinolone acetonide/neomycin sulphate/gramicidin/nystatin ointment, with the off-label use of clotrimazole 1% cream. This is to determine if clotrimazole (the only treatment of the three without risk of ototoxicity) is as efficacious as the current licensed treatments. Methods: A review of patients diagnosed with FOE from a single Victorian specialist Ear, Nose and Throat (ENT) hospital Emergency Department (ED) was undertaken. Data from a 6-month period (March 2021–September 2021) were collected. Any patient who had presented to the ED, was subsequently confirmed on microscopy results to have FOE, and was reviewed 2 weeks post-treatment in ENT clinic was included. Successful treatment was defined as no further treatment requirement at the 2-week review. Results: Fifty-eight patients met the inclusion criteria. Ten of 16 patients (63%) were successfully treated with flumetasone pivalate/clioquinol eardrops. Twenty of 30 patients (67%) were successfully treated with triamcinolone acetonide/neomycin sulphate/gramicidin/nystatin ointment. Seven of 12 patients (58%) were successfully treated with clotrimazole 1% cream. There was no statistically significant difference between successful treatment rates between the topical treatments (Chi-square: 0.27, P=0.87). Conclusions: Clotrimazole appears to be as efficacious in the management of FOE as other topical antifungal agents. Although used off-label, it is not associated with ototoxicity. It should be considered an appropriate first-line treatment for patients with FOE, especially in the setting of TMP.
- Open Access
- 8 February 2023
- Published by Wiley in Anz Journal of Surgery
- Vol. 93 (3) , 561-565
Transoral approach to accessory parotid tumours: case series and literature review
Accessory parotid tumours are rare, accounting for less than 10% of parotid neoplasms. Although similar tumours affect both the accessory parotid and parotid, accessory parotid tumours are associated with higher rates of malignancy. Surgery is first line management. Standard surgical management involves a similar approach to superficial parotidectomy, despite the anterior location of these lesions. This approach requires extensive subcutaneous access and facial nerve dissection and therefore, poses significant risk. It can also result in poor cosmetic result due to scarring and Frey's Syndrome. On the contrary, a transoral approach to reduces the risk of cosmetic deformity, reduces recovery time and does not increase risk to the facial nerve. We present a case series of patients with accessory parotid masses, which have been successfully excised transoral and without endoscopic assistance.
- 8 February 2023
- Published by Wiley in Anz Journal of Surgery
- Vol. 93 (3) , 561-565
Open AccessTransoral approach to accessory parotid tumours: case series and literature review
Accessory parotid tumours are rare, accounting for less than 10% of parotid neoplasms. Although similar tumours affect both the accessory parotid and parotid, accessory parotid tumours are associated with higher rates of malignancy. Surgery is first line management. Standard surgical management involves a similar approach to superficial parotidectomy, despite the anterior location of these lesions. This approach requires extensive subcutaneous access and facial nerve dissection and therefore, poses significant risk. It can also result in poor cosmetic result due to scarring and Frey's Syndrome. On the contrary, a transoral approach to reduces the risk of cosmetic deformity, reduces recovery time and does not increase risk to the facial nerve. We present a case series of patients with accessory parotid masses, which have been successfully excised transoral and without endoscopic assistance.